A large retrospective analysis of 237,043 patients with hip or knee OA, including 23,000 individuals exposed to GLP-1 agonists for at least 1 year, found that arthroplasty risk at 1 year was reduced by approximately 40% for hip replacement and 25% for knee replacement
It can be used by adults with a body mass index (BMI) greater than or equal to 30 mg/kg alone or 27 mg/kg with at least one weight-related condition (e.g., high blood pressure, high cholesterol, Type 2 diabetes)
wherein X is Boc or Trt Fmoc-Ser(tBu)-Tyr(tBu)-Leu-Glu(OtBu)-Gly-OH (fragment-3)
Its ability to help reduce obesity-related complications, such as cardiovascular disease, type 2 diabetes, and hypertension, makes it a promising option for long-term weight management
Authors' Contribution C
Why isn't my reconstituted GHK-Cu blue